ABSTRACT: Progress in sequencing technology is intrinsically linked to progress in understanding cancer genomics. The purpose of this review was to discuss the development from Sanger sequencing to nextgeneration sequencing (NGS) technology. We highlight the technical considerations for understanding reports using NGS. We discuss the findings of studies in head and neck cancer using NGS as well as The Cancer Genome Atlas. Finally we discuss future routes for research utilizing this methodology and the potential impact of this.
INTRODUCTION
Progress in cancer research has paralleled that of progress in the various technologies that can be utilized and exploited. One of the most remarkable developments in the last decade has been the advent of next-generation sequencing (NGS) technology. The human genome sequence was published in 2001. 1, 2 This ushered in a new era of scientific research, in which the correlation between genomic and phenotypic characteristics of disease could be made in new and promising ways.
Fearon and Vogelstein 3 demonstrated that morphological development of colorectal cancer occurs in parallel with a stepwise progressive accumulation of genetic alterations. Califano et al 4 created a similar model for the genetic basis of head and neck cancer. Since these landmark articles, one of the key theories driving cancer research has been that studying genetic changes across the entire genome (genomics) to identify alterations responsible for carcinogenesis and metastasis could lead to new therapies and insights into how to manage patients with cancer.
The purpose of this review was to explain the technological advances in sequencing and review their impact and discoveries thus far in head and neck cancer as well as discuss potential for the future.
Sanger sequencing
Sanger et al 5 described Sanger sequencing in 1977. This involved the copying of a template strand of DNA into radiolabeled complementary DNA (cDNA) strands. The synthesis of these strands is randomly terminated, and the sequence reconstructed from the final base of each strand. [5] [6] [7] The first genome to be sequenced was that of the bacteriophage phi X 174 (UX174). 8 This utilized Sanger technology to identify the 5386 nucleotides. Sanger sequencing is accurate but can only sequence DNA fragments up to 1000 bp in length. This would need to be performed 3 million times in order to sequence the human genome once. For limited sequencing, however, it is very cheap.
A progression in the rate of sequencing was achieved with shotgun Sanger sequencing. This utilized plasmid cloning to produce cDNA fragments for sequencing, allowing longer overall templates of DNA to be sequenced more rapidly. The first cellular organism genome to be published was hemophilus influenza in 1995. 9 This utilized shotgun sequencing to reveal the 1,830,140 base pairs. Shotgun sequencing was key in increasing the speed at which DNA could be sequenced, and was the workhorse approach that produced the first draft of the human genome. 1 In addition to the laborious techniques and short sequences, Sanger sequencing was also limited in the accuracy of the first 40 and last 100 bases to be sequenced because of primer binding. The accuracy is also affected by increasing levels of guanine-cytosine content in the DNA strands to be sequenced. Similarly, repetitive regions of DNA could also affect the accuracy of sequencing. 10 Although shotgun sequencing did enhance the rate of sequencing, and latterly this became more automated, it still suffered similar issues. 6 
Next-generation sequencing
This describes a technology that differs from Sanger sequencing and represents a huge step forward in terms of speed of sequencing. It is important to understand that NGS does not automatically mean whole genome sequencing (WGS) or whole exome sequencing (WES) (see Table  1 ). It is a technology as opposed to a specific application.
NGS involves the breaking up of a DNA sample into many millions of fragments of known average length (see Figure 1 ). Synthetic DNA "adaptors" are then bound to these fragments and labeled with an index primer (these are then referred to as DNA "libraries"). These fragments are then bound to a support matrix where an amplification reaction takes place followed by cycles of sequencing, which occur in parallel (leading to the term massively parallel sequencing). Signals are detected according to the nucleotides sequenced. Each DNA strand sequenced is termed a read. NGS has the capacity to produce hundreds of millions of reads. These are generally short (50-200 bases) and the huge numbers of reads requires considerable specialized computer resources to align these to the reference genome. The number of times the same area of the genome is sequenced is referred to as depth (or coverage) of sequencing. To produce more reliable data, the same area needs to be sequenced many times according to the type of information required. For instance, WGS requires higher coverage compared to copy number variation sequencing. There are, however, different platforms with variations in their chemistry. Each of these platforms can be used for sequencing DNA or RNA (see Table 2 ).
Roche
The Roche GS-FLX 454 Genome Sequencer (Basel, Switzerland) was the first commercially available platform (2004). These use an emulsion of beads as the matrix to which DNA libraries are bound. The amplification process ensures approximately 1 million copies of the same DNA fragment are bound to each bead. Nucleotides are then added and cDNA strands are synthesized via a pyrophosphate reaction (therefore, this is often referred to as pyrosequencing). This reaction produces a light signal proportional to the nucleotides detected by a camera and converted to sequencing "reads" by a computer. 11 The use of this to sequence an individual's complete genome was published in 2008. 12 This represented a huge drop in the cost of sequencing a person's genomes (less than $1 million compared to more than $100 million by Venter et al). 1, 12 Compared to other NGS platforms, the Roche 454 is fast (23 hours) and produces long reads (up to 1000 bp), although it cannot produce as many reads (therefore, Roche data are low in depth). There is also a benchtop version (the Roche GS Junior).
More importantly, Roche announced in 2013 that it plans to shut down production of the 454 platform, although it will continue supporting the current 454 sequencers already in use until 2016.
Illumina
The Illumina HiSeq (San Diego, CA) uses a specialized glass slide called a flow cell as the matrix to which adaptorligated DNA is bound. 13 These fragments are then amplified to form clusters of identical DNA fragments. Fluorescentlabeled nucleotides are added to allow sequencing-bysynthesis and the signal released is measured by a camera and translated to sequencing reads. This platform produces much more data than the Roche 454 in terms of depth of reads, although this does require experienced bioinformatics support. On high-output mode, it takes 2 weeks to run, although this can be modified. A cheaper, quicker model (MiSeq) can be used for targeted sequencing of a smaller region of the genome.
14 Illumina have also introduced both a benchtop HiSeq version and a larger machine to widen options in terms of cost and throughput.
Life Technologies
The Supported Oligonucleotide Ligation and Detection (SOLiD) platform uses magnetic beads to bind DNA libraries and undergo amplification by polymerase chain reaction (PCR). Four fluorescently labeled probes are added and ligate to the DNA library strands in a cyclical manner producing a signal, which is read by a camera. This is very precise in reading bases (99.99% accuracy) and produces good depth of reads, but can be relatively prone to errors because of technical issues preparing the libraries and running the system. 11, 14 Life Technologies (Carlsbad, CA) also produce the Ion Personal Genome Sequencer. This utilizes semiconductor technology (ion torrent technology) in a similar fashion to pyrosequencing. Known nucleotides are introduced and hydrogen ions are released if they are added to the cDNA strand. These produce a pH change, which is detected and proportional to the number of bases added. 14, 15 Single molecule sequencing
This involves sequencing single molecules of DNA without any amplification. The advantages of this are removal of any potential bias or inaccuracy produced by the amplification step, as well as potentially increased accuracy, speed of sequencing, and reduced cost. 14, 16, 17 The Helicos Heliscope system (Cambridge, MA) is still based on sequencing-by-synthesis and fluorescence detection. 16 Oxford Nanopore Technologies (Oxford, UK) is developing a system of single molecule sequencing utilizing a lipid bilayer porous membrane that DNA molecules adhere to and then pass through on application of an electric current. 17 The passage of different bases through a pore produces alterations in the current across the membrane, which is measurable. 18 FIGURE 1. Shown is the processing nucleic acid into a form for nextgeneration sequencing (NGS). (1) The genomic DNA has been extracted from the tissue sample. (2) This is then broken down into fragments of approximately equal maximum length. This is necessary as NGS produces sequencing reads of a fixed maximum length, dependent on the platform and settings. (3) 1 (4) Adaptor sequences and primers are ligated to the fragmented DNA in order for this to bind to the sequencing matrix and for each strand to be identifiable when analyzing the reads in the subsequent data. (5) The labelled DNA binds to a sequencing matrix and each strand undergoes an amplification process producing clusters that are all read many times, thus improving the accuracy of the sequencing. In the Illumina platform, the matrix takes the form of a glass slide, as shown above, although this can take the form of bead, as in the Roche platform. (6) Nucleotides are added and cDNA strands are synthesized from these. A laser is used to make the nucleotides fluoresce. This signal is detected and converted into sequencing reads.
This type of sequencing is sometimes referred to as third generation sequencing, and accuracy of these platforms is still under investigation.
Technical considerations
In addition to the different platforms, there are several technical considerations to understand in the production and analysis of NGS data.
Laboratory
The source of the nucleic acid is important. Cell lines, fresh tissue, and formalin-fixed paraffin-embedded (FFPE) tissue are all potential sources. Cell lines can enable replicable results, although genomic differences between cell lines and primary human cells have been described. 19 Fresh tissue is a good source of high quality nucleic acid, although it can be more time-consuming to obtain. The archives of FFPE tissue around the world present huge potential in terms of numbers of samples. They also offer the advantage that follow-up data are often more easily and rapidly available for these samples. This nucleic acid is degraded and can be more challenging to work with as well as containing artifacts from the formalin-fixation process. 20 Techniques have improved so that FFPE tissue is increasingly being used. 21, 22 The purity of the source cell type is important. Tumor samples frequently contain mixed populations of cancerous epithelial cells, normal epithelium, lymphocytes, and stromal cells. These noncancerous, nonepithelial cells also contain nucleic acid, which can create "noise" masking the signal of the target cell. Previously, a minimum of 70% tumor cell fraction had been thought of as necessary, although with NGS this issue can be tackled a number of ways. By increasing the depth of sequencing, anomalies that are only present in a smaller fraction of the cells being sampled can be detected. 23 The head and neck squamous cell carcinoma (HNSCC) samples used by The Cancer Genome Atlas (TCGA) had a median tumor cell fraction of approximately 50% and it is likely that much lower fractions will still yield very useful information. 24 This issue can also be accounted for with the development of algorithms that can enable lower fraction genomic anomalies to be identified, even with lower numbers of reads. 25 
Cost
Sequencing costs have dropped dramatically since 2001, as shown in Figure 2 . This data from the National Human Genome Research Institute compares DNA sequencing costs to a hypothetical trend described by Moore's Law (this predicts the trend of doubling in computing power associated with a decrease in hardware costs). 26 
Bioinformatics
Although the costs of sequencing a sample of DNA have reduced considerably, the data produced requires varying amounts of analysis. This is a challenging, specialized skill. Both academic and commercial institutes, with an interest in NGS, are currently investing heavily in bioinformatics. This cost is often not accounted for in claims of the "$1000 genome." 27 Bioinformatics is key in the analysis of NGS data and in accounting for potential error. Sources of error in NGS include PCR artifact. Many NGS methodologies involve 1 or more PCR steps, during which errors in PCR replication can cause mismatches in the alignment to the reference genome, causing essentially a false-positive results. Similarly, PCR steps inevitably produce duplicates of the same segments of nucleic acid. These waste sequencing reads and, if there are excessive amounts, reduce the accuracy of sequencing overall. 28, 29 Inaccuracy in the sequencing platform calling (recognizing) bases is also an issue. This is referred to as sequencing error and varies in reports from 1 in 1000 bases to 1 in 10,000,000 bases. 30, 31 Although these seem low, given the billions of bases sequenced with each run, this is significant. Attempts to reduce this error include increasing read depth (the number of times each DNA strand is sequenced), using technical replicates (sequencing the same library repeatedly to identify error), and biological replicates (multiple samples from the same cell type to identify random errors and repetitive abnormalities). 28, 32 The primary aim of the bioinformatician is to process and analyze the raw NGS data with accurate "calling" of anomalies (whether mutation, copy number, etc.) and minimizing the rate of false-positive results. The degree of variation for cancer genomes compared to the reference genome varies considerably. Adjustments must therefore be made for the sample's background anomaly rate, ploidy, and purity. 23 For example, if a sample contained 50% tumor DNA and a mutation is present on 1 arm of a triploid chromosome, this will only be present in 16.6% of the sequenced reads. 23 The depth of sequencing will influence the ability to detect a mutation, such as this, as will the presence of a matched normal sample, also sequenced at sufficient depth. An error can be made because of detecting a germline event in the tumor and failing to detect it in the normal sample or when a mutation is mistakenly called in the tumor when both the tumor and normal are wild-type. 23, 25 The presence of important low frequency mutations in clonal subpopulations within the sample is another confounding issue. Sequencing depth and the use of algorithms that are stable in the presence of data from genomically heterogeneous tumors, such as HNSCC is essential.
New methods of analyzing NGS to produce more accurate results or to discover clinically relevant patterns are produced every month. [33] [34] [35] Much of this data are essentially open source and available for download (eg, CNAnorm, a program available from Bioconductor.org designed to estimate copy number aberrations in cancer samples). 36 Considerable effort is required to keep abreast of these as well as the ongoing results of sequencing being published.
Specifically for head and neck cancer, the Mutant Allele Tumor Heterogeneity algorithm was developed to measure intratumor heterogeneity from publically available exome sequencing data. 37, 38 A higher Mutant Allele Tumor Heterogeneity measure was found to be associated with specific groups of head and neck cancer with poorer outcome (those with TP53 mutations, human papillomavirus [HPV]-negative and HPV-negative tumor with increased smoking pack-year history). 37 
Next-generation sequencing and head and neck cancer
The first major studies in the use of NGS in HNSCC were published in 2011. 38, 39 These 2 studies together performed whole exome sequencing on 106 patients with HNSCC in total. These included oral, oropharyngeal, laryngeal, hypopharyngeal, and sinonasal tumors. It also included HPV-positive and negative tumors. These studies confirmed the findings of previous genomic work that TP53 was the most commonly mutated gene in HNSCC and also discovered the second most commonly mutated gene was NOTCH1 (in around 15% of patients). 38, 39 This was the first time NOTCH1 had been implicated in HNSCC.
Interestingly, these studies also found that HPVpositive tumors had approximately half the mutation rate of HPV-negative tumors. 38, 39 On analyzing subgroups, they also found smokers had a higher rate of guanosine to thymidine point mutations, in addition to having a higher rate of mutations. In general, they found around 130 mutated genes per sample. The surprisingly low proportion of recurring mutations could be related to the mix of subsites reducing the number in each group, but gives a picture that each head and neck tumor is genomically quite different from the next.
In a follow-up publication by Lui et al 40 in 2013, a further 45 tumors had undergone whole exome sequencing, making a total of 151 sequenced tumors available for analysis. Again, a large number of mutated genes were identified per sample and a high degree of intertumor mutational heterogeneity was observed. Developing their analysis, they focused on specific functional pathways that had previously been identified as targetable in cancer. By doing this, they found 31% of HNSCC in their cohort contained phosphoinositide 3-kinase (PI3K) pathway mutations. This signaling axis has been shown to have a role in cancer cell growth, survival, motility, and metabolism. [41] [42] [43] Lui et al 40 found that PI3K-pathway mutated HNSCC contained a higher rate of mutations in known cancer genes and that those with concurrent mutations in PI3K pathway genes were all advanced tumors implicating his pathway in HNSCC progression. This study highlighted the potential for NGS to identify therapeutic targets and biomarkers in HNSCC.
Integrative genomics is a burgeoning research area and the combination of NGS data with other techniques was demonstrated by Pickering et al 44 who used exome sequencing in 40 patients with oral squamous cell carcinoma with single-nucleotide polymorphism array copy number data, gene expression and miRNA expression as well as DNA methylation. They identified 4 major driver pathways in oral squamous cell carcinoma, including mitogenic signaling, Notch, cell cycle, and TP53. Although a small group, they also highlighted 2 subgroups defined by the key genes FAT1 and CASP8. This approach also identified currently and potentially targetable genomic anomalies.
The TCGA has performed comprehensive genomic analysis of 279 untreated HNSCC cases. 45 This included whole exome sequencing, WGS, and whole transcriptome sequencing, as well as miRNA, DNA methylation, and copy number profiling. Thirty-six of the tumors were HPV-positive and 243 were HPV-negative. The majority of tumors were oral cavity and laryngeal (n 5 244 of 279; 87%). Of 33 oropharyngeal tumors, they found 64% were HPV-positive, whereas only 6% of nonoropharyngeal tumors were HPV-positive. 45 The TCGA found HPV-positive and negative tumors to have an overall different mutation profile, with HPVpositive tumors exhibiting infrequent mutations in TP53, CDKN2A, FAT1, and AJUBA. They found 86% of HPVnegative tumors harbored TP53 mutations, whereas only 1 of 36 HPV-positive tumors had a TP53 mutation. Although PIK3CA was found to be mutated in both HPV-positive and negative tumors, a specific mutation of the helical domain of PIK3CA was predominant in HPVpositive tumors -an important finding when considering targetable events. EGFR was found to be rarely mutated in HPV-positive tumors compared to HPV-negative tumors. 45 This could have serious implications regarding the use of EGFR-inhibitors in these patients.
The larger numbers involved in the TCGA do lend a greater credence to their ability to analyze subgroups. They confirmed previously reported gene expression subtypes (atypical, mesenchymal, basal, and classical). [45] [46] [47] Using an integrated approach, they were able to identify genomic markers and suggest pathways associated with each subtype.
The India Project Team of the International Cancer Genome Consortium demonstrated the advantages of concentrating resources and collaborative efforts by reported whole exome sequencing on 50 gingivo-buccal SCCs (GBSCCs) and targeted resequencing on a further 60 GBSCCs. 24 It is vital that genomic patterns identified in different cohorts of HNSCC are not mistakenly assumed to be present in another. The prevalence of betel quid chewing in South-East Asia means a different profile of HNSCC is seen in this region. This study identified 5 new genes associated with GBSCC and 3 molecular subgroups demonstrating different disease-free survival.
Increasingly, important therapeutic subgroups of patients with HNSCC will be discovered as the numbers of tumors being sequenced grows. This is important in the effort toward "personalized medicine." Part of the revolution being driven by NGS will be the shift away from purely classifying tumors by pathologic criteria and integrating genomic subgroups that are clinically relevant and will guide treatment decisions. Gross et al took advantage of the TCGA data available (WES, copy number variation, mRNA, and miRNA expression) and combined 250 patients with HPV16-negative cancers, aged under 85 years. 48 They were able to link loss of 3p with TP53 mutation as a marker for significantly decreased survival (1.9 years compared to >5 years for TP53 mutation alone). They also identified mir-548k expression as an additional marker for further reduced survival.
Another study performed whole exome sequencing on 16 younger nonsmokers with oral tongue cancer (<45 years old) and 28 older smokers.
49 Surprisingly, this study found the 2 groups to be genomically similar. On interrogating TCGA data for lung adenocarcinoma, bladder urothelial carcinoma, and HNSCC, a smoking mutation signature was generated. Both young and older oral tongue cancers were found to be most similar to a nonsmoking mutation profile. Admittedly, this is a small group of uncommon cancers but the combination of individual study data with TCGA data is a good example of the accumulative power of NGS.
Targeted sequencing could also be useful in confirming a cell line mutational profile when attempting to demonstrate in vitro efficacy of targeted therapies, although of course the lack of epigenetic factors must be borne in mind. 50 NGS also has applications for the determination of HPV status. This technology can be used to detect copies of HPV DNA within the sample being sequenced. It also has the advantage that all subtypes of HPV can be screened for simultaneously. 51 This can be achieved with low-coverage and relatively low-cost NGS technology and can be performed as an additional analysis of the same sequencing data being obtained for other purposes at no extra cost. Issues with the use of this technology relate to the fact that detection of a single copy of HPV DNA within the sample does not mean the tumor was driven by HPV and there is no accepted standard for the number of detectable copies that should be regarded as a positive result. Work in cervical cancer certainly shows promise for an NGS-based high-risk HPV genotyping assay. 52 Conway et al 51 found NGS to be comparable to PCR and p16 immunohistochemistry with excellent specificity. It has also been used to screen a large number of oral verrucous carcinoma samples for all subtypes of HPV establishing the scarcity of HPV in this type of oral cancer. 53 RNAseq has also been used to evaluation HPV16 expression in 7 young patients (average age, 37 years) with oral tongue tumors. 54 This study found that these patients had a poor prognosis and found no evidence of HPV16 expression. Seiwert et al, 55 compared targeted exome sequencing and copy number profiles of 51 HPV16-positive and 69 HPV16-negative tumors. They found a similar overall mutational burden in both groups, although unique mutations in DDX3X and FGFR2/3 were found in HPV16-positive tumors.
Chung et al 46 used NGS to investigate the tumor-host interaction in HPV16-positive HNSCC. They examined whole genome sequencing and DNA methylation profiles in 35 HPV-positive tumors and compared these to 270 HPV16-negative samples from the TCGA cohort. Whole genome sequencing allowed them to identify sites of integration of HPV DNA into the host genome. By doing this, they were able to identify cancer genes at the sites of integration that were potentially disrupted and involved in the carcinogenic mechanism in virally driven HNSCC.
The issue of intratumor heterogeneity has gained increasing prominence recently with landmark studies in renal cell carcinoma using NGS to demonstrate clearly significant mutational difference in different samples from the same tumor. 56, 57 The potential impact of this on the use of genomic biomarkers to guide treatment and clinical trials is huge. Three samples from a single oropharyngeal tumor and 2 samples from its corresponding cervical metastasis underwent whole genome sequencing in a study by Zhang et al. 58 They found only 41% of all somatic point mutations were shared across all 5 samples. Although this concurred with larger studies, clearly, the high cost and singular workload in applying this technology is demonstrated with only the ability to analyze 1 tumor. This cost is continuing to come down but CNVseq or targeted sequencing of a smaller panel of known genes could be used to demonstrate genomic heterogeneity at lower cost.
CONCLUSION
NGS technology has revealed significant genomic characteristics of HNSCC. The technology available is advancing continually as are the methods for analyzing the data produced. In light of this, it is important for raw NGS data obtained by different groups to be made publicly available after publication. The ability to add to the pool of data is vital for tumors that are less common, such as HNSCC. The issue of subsite signatures and subgroups according to ethnicity, inheritance, HPV, and smoking, among others, is also a reason to try and pool data in order to increase the power of available data. Projects such as Head and Neck 5000 present a fantastic opportunity for large numbers of tissue and blood to be interrogated, although these attempts need to be carefully planned to avoid wasting resources. 59 Precancer in HNSCC still requires analysis using NGS technology with comparison to spatially and temporally related cancer in order to help divine tumor promoters and drivers.
Since the first draft of the human genome was produced, the cost of WGS has dropped from approximately a billion dollars to a couple of thousand dollars. The speed at which this data can be obtained has gone from years to 2 weeks. Advancements will continue to be made to improve accuracy and data processing. The information gleaned from NGS will be collated and combined with clinicopathologic data on an increasingly large scale. Combining NGS with other genomic approaches on a large scale will reveal biomarkers and therapeutic targets. This will enable the development of clinically relevant, molecular subgroups that will guide treatment.
